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ABSTRACT 
 
Impaired lung function is often caused by cigarette smoking, making it challenging to disentangle its role 
in lung cancer susceptibility. Investigation of the shared genetic basis of these phenotypes in the UK 
Biobank and International Lung Cancer Consortium (29,266 cases, 56,450 controls) shows that lung 
cancer is genetically correlated with reduced forced expiratory volume in one second (FEV1: rg=0.098, 
p=2.3´10-8) and the ratio of FEV1 to forced vital capacity (FEV1/FVC: rg=0.137, p=2.0´10-12). Mendelian 
randomization analyses demonstrate that reduced FEV1 increases squamous cell carcinoma risk (odds 
ratio (OR)=1.51, 95% confidence intervals: 1.21-1.88), while reduced FEV1/FVC increases the risk of 
adenocarcinoma (OR=1.17, 1.01-1.35) and lung cancer in never smokers (OR=1.56, 1.05-2.30). These 
findings support a causal role of pulmonary impairment in lung cancer etiology. Integrative analyses 
reveal that pulmonary function instruments, including 73 novel variants, influence lung tissue gene 
expression and implicate immune-related pathways in mediating the observed effects on lung 
carcinogenesis. 
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INTRODUCTION 
Lung cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer 
mortality1. Although tobacco smoking remains the predominant risk factor for lung cancer, clinical 
observations and epidemiological studies have consistently shown that individuals with airflow limitation, 
particularly those with chronic obstructive pulmonary disease (COPD), have a significantly higher risk of 
developing lung cancer2, 3, 4, 5, 6, 7. Several lines of evidence suggest that biological processes resulting in 
pulmonary impairment warrant consideration as independent lung cancer risk factors, including 
observations that previous lung diseases influence lung cancer risk independently of tobacco use6, 8, 9, 10, 
and overlap in genetic susceptibility loci for lung cancer and chronic obstructive pulmonary disease 
(COPD) on 4q24 (FAM13A), 4q31 (HHIP), 5q.32 (HTR4), the 6p21 region, and 15q25 
(CHRNA3/CHRNA5)11, 12, 13, 14. Inflammation and oxidative stress have been proposed as key 
mechanisms promoting lung carcinogenesis in individuals affected by COPD or other non-neoplastic lung 
pathologies9, 11, 15.  
Despite an accumulation of observational findings, previous epidemiological studies have been unable to 
conclusively establish a causal link between indicators of impaired pulmonary function and lung cancer 
risk due to the interrelated nature of these conditions7. Lung cancer and obstructive pulmonary disease 
share multiple etiological factors, such as cigarette smoking, occupational inhalation hazards, and air 
pollution, and 50-70% of lung cancer patients present with co-existing COPD or airflow obstruction6. 
Furthermore, reverse causality remains a concern since pulmonary symptoms may be early 
manifestations of lung cancer or acquired lung diseases in patients whose immune system has already 
been compromised by undiagnosed cancer. 
Disentangling the role of pulmonary impairment in lung cancer development is important from an 
etiological perspective, for refining disease susceptibility mechanisms, and for informing precision 
prevention and risk stratification strategies. In this study we comprehensively assess the shared genetic 
basis of impaired lung function and lung cancer risk by conducting genome-wide association analyses in 
the UK Biobank cohort to identify genetic determinants of three pulmonary phenotypes, forced expiratory 
volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC. We examine the genetic 
correlation between pulmonary function phenotypes and lung cancer, followed by Mendelian 
randomization (MR) using novel genetic instruments to formally test the causal relevance of impaired 
pulmonary function, using the largest available dataset of 29,266 lung cancer cases and 56,450 controls 
from the OncoArray lung cancer collaboration16. 
 
RESULTS 
Heritability and Genetic Correlation 
Array-based, or narrow-sense, heritability (hg) estimates for all lung phenotypes were obtained using LD 
score regression17 based on summary statistics from our GWAS of the UKB cohort (n=372,750 for FEV1, 
n=370,638 for FVC, n=368,817 for FEV1/FVC; Supplementary Figure 1) are presented in Table 1. 
Heritability estimates based on UKB-specific LD scores (n=7,567,036 variants), were consistently lower 
but more precise than those based on the 1000 Genomes (1000 G) Phase 3 reference population 
(n=1,095,408 variants). For FEV1, hg = 0.163 (SE=0.006) and hg = 0.201 (SE=0.008), based on UKB and 
1000G LD scores, respectively. Estimates for FVC were hg = 0.175 (SE=0.007) and hg = 0.214 
(SE=0.010). Heritability was lower for FEV1/FVC: hg = 0.128 (SE=0.006) and 0.157 (SE=0.010), based on 
internal and 1000G reference panels, respectively. For all phenotypes, hg did not differ by smoking status 
and estimates were not affected by excluding the major histocompatibility complex (MHC) region.  
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Partitioning heritability by functional annotation identified large and statistically significant (p<8.5´10-4) 
enrichments for multiple categories (Figure 1; Supplementary Tables 1-3). A total of 35 categories, 
corresponding to 22 distinct annotations, were significantly enriched for all three pulmonary phenotypes, 
including annotations that were not previously reported18. Large enrichment, defined as the proportion of 
heritability accounted for by a specific category relative to the proportion of SNPs in that category, was 
observed for elements conserved in primates19, 20 (17.6% of SNPs, 54.7-58.5% of hg), McVicker 
background selection statistic21, 22 (17.8% of SNPs, 22.6-25.1% of hg), flanking bivalent transcription 
starting sites (TSS)/enhancers from Roadmap20, 23 (1.4% of SNPs, 11.1-13.2% of hg), and super 
enhancers (16.7% of SNPs, 33.9-38.6% of hg). We also replicated previously reported significant 
enrichments for histone methylation and acetylation marks H3K4me1, H3K9Ac, and H3K27Ac18, 24. 
Substantial genetic correlation was observed for pulmonary phenotypes with body composition and 
smoking traits, mirroring phenotypic correlations in epidemiologic studies (Figure 2). Large positive 
correlations with height were observed for FEV1 (rg=0.568, p=2.5´10-567) and FVC (rg=0.652, p=1.8´10-
864). Higher adiposity was negatively correlated with FEV1 (BMI: rg=-0.216, p=4.2´10-74; percent body fat: 
rg=-0.221, p=1.7´10-66), FVC (BMI: rg=-0.262, p=1.6´10-114; percent body fat: rg=-0.254, p=1.2´10-88). 
Smoking status (ever vs. never) was significantly correlated with all lung function phenotypes (FEV1 rg=-
0.221, p=8.1´10-78; FVC rg=-0.091, 1.0´10-16; FEV1/FVC rg=-0.360, p=7.5´10-130). Cigarette pack years 
and impaired lung function in smokers were also significantly genetically correlated with FEV1 (rg=-0.287 
p=1.1´10-35), FVC (rg=-0.253, p=1.9´10-30), and FEV1/FVC (rg=-0.108, p=3.0´10-4). As a positive control, 
we verified that FEV1 and FVC were genetically correlated with each other (rg=0.922) and with FEV1/FVC 
(FEV1: rg=0.232 p=4.1´10-32; FVC: rg= -0.167 p=1.0´10-19).  
Genetic correlations between lung function phenotypes and lung cancer are presented in Figure 3. For 
simplicity of interpretation coefficients were rescaled to represent genetic correlation with impaired 
(decreasing) lung function. Impaired FEV1 was positively correlated with lung cancer overall (rg=0.098, 
p=2.3´10-8), squamous cell carcinoma (rg=0.137, p=7.6´10-9), and lung cancer in smokers (rg=0.140, 
p=1.2´10-7). Genetic correlations were attenuated for adenocarcinoma histology (rg=0.041, p=0.044) and 
null for never-smokers (rg=-0.002, p=0.96). A similar pattern of associations was observed for FVC. 
Reduced FEV1/FVC was positively correlated with all lung cancer subgroups (overall: rg=0.137, p=2.0´10-
12; squamous carcinoma: rg=0.137, p=4.3´10-8; adenocarcinoma: rg=0.125, p=7.2´10-9; smokers: 
rg=0.185, p=1.4´10-10), except for never smokers (rg=0.031, p=0.51). 
Exploring the functional underpinnings of these genetic correlations revealed three functional categories 
that were significantly enriched for lung cancer (Supplementary Table 4), and have not been previously 
reported25. All these categories were also significantly enriched for pulmonary traits. CpG dinucleotide 
content22 included only 1% of SNPs, but had a strong enrichment signal for lung cancer (p=2.1´10-7), 
FEV1 (p=7.7´10-24), FVC (p=2.3´10-23, and FEV1/FVC (p=3.8´10-17). Other shared features included 
background selection (lung cancer: p=1.0´10-6, FEV1: p=1.9´10-20, FVC: p=6.9´10-23, FEV1/FVC: 
p=1.5´10-15) and super enhancers (lung cancer: p=4.4´10-6, FEV1: p=3.4´10-24, FVC: p=5.1´10-20, 
FEV1/FVC: p=9.6´10-22).  
Genome-Wide Association Analysis for Instrument Development 
Based on the results of our GWAS in the UK Biobank, we identified 207 independent instruments for 
FEV1 (P<5´10-8, replication P<0.05; LD r2<0.05 within 10,000 kb), 162 for FVC, and 297 for FEV1/FVC. 
We confirmed that our findings were not affected by spirometry performance quality, with a nearly perfect 
correlation between effect sizes (R2=0.995, p=2.5´10-196) in the main discovery analysis and after 
excluding individuals with potential blow acceptability issues (Field 3061≠0; n=60,299). After applying 
these variants to the lung cancer OncoArray dataset and selecting LD proxies (r2>0.90) for unavailable 
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variants, the final set of instruments consisted of 193 variants for FEV1, 144 for FVC, and 264 SNPs for 
FEV1/FVC (Supplementary Data 1-3), for a total of 601 instruments. The proportion of trait variation 
accounted for by each set of instruments was estimated in the UKB replication sample consisting of over 
110,00 individuals (Supplementary Figure 1), and corresponded to 3.13% for FEV1, 2.27% for FVC, and 
5.83% for FEV1/FVC. We also developed instruments specifically for never smokers based on a separate 
GWAS of this population, which yielded 76 instruments for FEV1, 112 for FEV1/FVC, and 57 for FVC, 
accounting for 2.06%, 4.21%, and 1.36% of phenotype variation, respectively (Supplementary Data 4-6).  
After removing overlapping instruments between pulmonary phenotypes and LD-filtering (r2<0.05) across 
the three traits, 447 of the 601 variants were associated with at least one of FEV1, FVC, or FEV1/FVC 
(P<5´10-8, replication P<0.05). We compared these 447 independent variants to the 279 lung function 
variants recently reported by Shrine et al.18 based on an analysis of the UK Biobank and SpiroMeta 
consortium, by performing clumping with respect to these index variants (LD r2<0.05 within 10,000 kb). 
Our set of instruments included an additional 73 independent variants, 69 outside the MHC region 
(Supplementary Table 5), that achieved replication at the Bonferroni-corrected threshold for each trait 
(maximum replication P = 2.0´10-4).  
Our instruments included additional independent signals in known lung function loci and variants in genes 
newly linked to lung function, such as HORMAD2 at 22q12.1 (rs6006399: PFEV1=1.9´10-18), which is 
involved in synapsis surveillance in meiotic prophase, and RIPOR1 at 16q22.1 (rs7196853: P FEV1/FVC 
=1.3´10-16), which plays a role in cell polarity and directional migration. Several new variants further 
support the importance of the tumor growth factor beta (TGF-b) signaling pathway, including CRIM1 
(rs1179500: PFEV1/FVC=3.6´10-17) and FGF18 (rs11745375: PFEV1/FVC=1.6´10-11). Another novel gene, 
PIEZO1 (rs750739: PFEV1=1.8´10-10), encodes a mechano-sensory ion channel, supports adaptation to 
stretch of the lung epithelium and endothelium, and promotes repair after alveolar injury26, 27. In never 
smokers a signal was identified at 6q15 in BACH2 (rs58453446: PFEV1/FVC-nvsmk=8.9´10-10), a gene 
required for pulmonary surfactant homeostasis. Lastly, two lung function variants mapped to genes 
somatically mutated in lung cancer: EML4 (rs12466981: PFEV1/FVC=2.7´10-14) and BRAF (rs13227429: 
PFVC=5.6´10-9).  
Mendelian Randomization 
The causal relevance of impaired pulmonary function was investigated by applying genetic instruments 
developed in the UK Biobank to the OncoArray lung cancer dataset, comprised of 29,266 lung cancer 
cases and 56,450 controls (Supplementary Table 6). Primary analyses were based on the maximum 
likelihood (ML) and inverse variance weighted (IVW) multiplicative random effects estimators28, 29. 
Sensitivity analyses were conducted using the weighted median (WM) and robust adjusted profile score 
(RAPS) estimators30, 31. A genetically predicted decrease in FEV1 was significantly associated with 
increased risk of lung cancer overall (ORML=1.28, 95% CI: 1.12-1.47, p=3.4´10-4) and squamous 
carcinoma (ORML=2.04, 1.64-2.54, p=1.2´10-10), but not adenocarcinoma (ORML=0.99, 0.83-1.19, p=0.96) 
(Figure 4; Supplementary Table 7). The association with lung cancer was not significant across all 
estimators (ORWM=1.06, p=0.57; ORRAPS=1.13, p=0.26). There was no evidence of directional pleiotropy 
based on the MR Egger intercept test (b0 Egger ¹0, p<0.05), but significant heterogeneity among SNP-
specific causal effect estimates was observed, which may be indicative of balanced horizontal pleiotropy 
(lung cancer: PQ=2.1´10-41; adenocarcinoma: PQ=3.4´10-9; squamous carcinoma: PQ=1.1´10-30). After 
excluding outlier variants contributing to this heterogeneity, 36 for lung cancer and 34 for squamous 
carcinoma, the association with FEV1 diminished for both phenotypes (lung cancer: ORML=ORIVW=1.12, 
p=0.13), but remained statistically significant for squamous carcinoma (ORIVW=1.51, 1.21-1.88, p=2.2´10-
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4), with comparable effects observed using other estimators (ORML=1.50, p=6.7´10-4; ORRAPS=1.48, 
p=1.7´10-3; ORWM=1.44, p=0.040). 
Genetic predisposition to reduced FVC was inconsistently associated with squamous carcinoma risk 
(ORML=1.68, p=1.8´10-4; ORWM=1.19, p=0.38). Effects became attenuated and more similar after 
removing outliers (ORML=1.27, p=0.10; ORRAPS=1.25, p=0.14) (Figure 4; Supplementary Table 8). A 
genetically predicted 10% decrease in FEV1/FVC was associated with an elevated risk of lung cancer in 
some models (ORML=1.18, 1.07-1.31, p=1.6´10-3), but not others (ORWM=1.10, p=0.30; ORRAPS=1.11, 
p=0.14) (Figure 4; Supplementary Table 9). The association with squamous carcinoma was also 
inconsistent across estimators. After removing outliers contributing to significant effect heterogeneity 
(lung cancer: PQ=1.2´10-28; adenocarcinoma: PQ=3.4´10-9; squamous carcinoma: PQ=5.3´10-15), the 
association with adenocarcinoma strengthened (ORML=1.17, 1.01-1.35; ORRAPS=1.18, 1.02-1.38), while 
associations for lung cancer and squamous carcinoma became attenuated.  
We examined the cancer risk in never smokers, by applying genetic instruments developed specifically in 
this population, to 2355 cases and 7504 controls (Figure 5; Supplementary Table 10). A genetically 
predicted 1-SD decrease in FEV1 and FVC was not associated with lung cancer risk in never smokers. 
However, a 10% reduction in FEV1/FVC was associated with a 61% increased risk (ORML=1.61, 1.10-
2.35, p=0.014; ORIVW=1.60, p=0.030). Outlier filtering did not have an appreciable impact on the results 
(ORML=1.56, 1.05-2.30, p=0.027; ORIVW=1.55, 1.05-2.28, p=0.028). A sensitivity analysis applied to 264 
FEV1/FVC instruments not specific to never smokers yielded an attenuated estimate (ORIVW=1.35, 1.03-
1.75, p=0.027), but confirmed the impact of FEV1/FVC reduction on lung cancer risk. 
For completeness, we also present MR estimates for the effect of impaired pulmonary function on lung 
cancer risk in smokers (Supplementary Table 11). Despite the larger sample size (23,223 cases and 
16,964 controls) compared to never smokers, a genetically predicted 10% reduction in FEV1/FVC was 
weakly and inconsistently associated with lung cancer risk (ORIVW=1.15, p=0.038; ORRAPS=1.08, 
p=0.488). Genetic predisposition to FEV1 and FVC impairment did not appear to confer an increased risk 
among smokers. 
Extensive MR diagnostics are summarized in Supplementary Table 12. All analyses used strong 
instruments (F-statistic > 40) and did not appear to be weakened by violations of the no measurement 
error (NOME) assumption (I2GX statistic >0.97). MR Steiger test32 was used to orient the causal effects 
and confirmed that instruments for pulmonary function were affecting lung cancer susceptibility, not the 
reverse, and this direction of effect was highly robust. No instruments were removed based on Steiger 
filtering. We also confirmed that none of the genetic instruments were associated with nicotine 
dependence phenotypes (P<1´10-5), such as time to first cigarette, difficulty in quitting smoking, and 
number of quit attempts, which were available for a subset of individuals in the UKB. All MR analyses 
were adequately powered, with >80% power to detect a minimum OR of 1.25 for FEV1 and FEV1/FVC 
(Supplementary Figure 2). For never smokers, we had 80% power to detect a minimum OR of 1.40 for 
FEV1/FVC and 1.60 for FEV1.  
Given the genetic correlation observed for pulmonary phenotypes cigarette smoking and adiposity, we 
conducted several sensitivity analyses to further address any potential confounding by these phenotypes. 
The finding for squamous carcinoma and FEV1 was further interrogated using multivariable MR (MVMR) 
by incorporating genetic instruments for BMI33 and smoking behavior34 to estimate the direct effect of 
FEV1 on squamous carcinoma risk. MVMR using all instruments yielded an OR of 1.95 (95% CI: 1.36-
2.80, p=2.8´10-4) per 1-SD decrease in FEV1 and an OR of 1.63 (95% CI: 1.20-2.23, p=1.8´10-3) after 
filtering outlier instruments.  
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We confirmed that none of the genetic instruments were associated with smoking status (ever/never), 
cigarette pack-years (continuous), or adiposity (body fat percentage) at the P < 5´10-8 level. However, 
several variants were associated based on a P < 1´10-5 threshold (25 for FEV1 and 18 for FEV1/FVC). We 
repeated MR analyses after removing these variants (Supplementary Table 13) and confirmed that our 
results remained robust for FEV1 and squamous cell carcinoma (ORIVW=2.02, 1.40-2.92, p=1.9´10-4) and 
FEV1/FVC and adenocarcinoma (ORIVW=1.19, 1.01-1.40, p=0.04). However, there was still significant 
heterogeneity among the causal effect estimates. After filtering the remaining outliers, the effect of a 10% 
decrease in FEV1/FVC on adenocarcinoma strengthened (ORIVW=1.24, 1.08-1.43, p=2.4´10-3), while 
estimates attenuated slightly for FEV1 and squamous carcinoma (ORIVW=1.46, 1.14-1.87, p=2.7´10-3). 
We also considered the possibility of residual confounding in our GWAS due to insufficient adjustment for 
smoking-related factors. We thus re-estimated SNP effects on FEV1, FVC, and FEV1/FVC with 
adjustment for continuous cigarette pack-years and years since quitting. The distribution of effect sizes 
did not differ between the two analyses (p>0.05), and the correlation with our original instrument weights 
was strong for all phenotypes (Pearson’s r ≥ 0.87, p<1´10-40) (Supplementary Figure 3). 
Lastly, we examined the association between FEV1 and FEV1/FVC genetic instruments and COPD, 
defined as FEV1/FVC<0.70. Among FEV1 instruments, 64% (123 variants) were associated with COPD at 
p<0.05 and 16% (31 variants) at p<5´10-8 (Supplementary Figure 4). All instruments for FEV1/FVC were 
associated with COPD at the nominal level, and 40% (105 variants) reached genome-wide significance. 
Using weights from estimated associations between the 105 instruments and COPD log(OR), we 
observed a modestly increased risk of lung adenocarcinoma (ORIVW=1.08, 1.01-1.15, p=0.015), which 
parallels our findings based on instruments developed for the continuous FEV1/FVC phenotype.  
Functional Characterization of Lung Function Instruments 
To gain insight into biological mechanisms mediating the observed effects of impaired pulmonary function 
on lung cancer risk, we conducted in-silico analyses of functional features associated with the genetic 
instruments for each lung phenotype.  
We identified 185 statistically significant (Bonferroni p<0.05) cis-eQTLs for 101 genes among the genetic 
instruments for FEV1 and FEV1/FVC based on lung tissue gene expression data from the Laval biobank35 
(Supplementary Data 7). Predicted expression of 7 genes was significantly (p<5.0´10-4) associated with 
lung cancer risk: SECISBP2L, HLA-L, DISP2, MAPT, KANSL1-AS1, LRRC37A4P, and PLEKHM1 
(Supplementary Figure 5). Of these, SECISBP2L (OR=0.80, p=5.2´10-8), HLA-L (OR=0.84, p=1.6´10-6), 
and DISP2 (OR=1.25, p=1.6´10-4) displayed consistent directions of effect for pulmonary function and 
lung cancer risk, whereby alleles associated with increased expression were associated with impaired 
FEV1 or FEV1/FVC and increased cancer risk (or conversely, positively associated with pulmonary 
function and inversely associated with cancer risk). Gene expression associations with inconsistent 
effects are more likely to indicate pleiotropic pathways not operating primarily through pulmonary 
impairment. Differences by histology were observed for SECISBP2L, which was associated with 
adenocarcinoma (OR=0.54, p=3.1´10-14), but not squamous cell carcinoma (OR=1.05, p=0.44). Effects 
observed for DISP2 (OR=1.21, p=0.021) and HLA-L (OR=0.90, p=0.034) were attenuated for 
adenocarcinoma, but not for squamous carcinoma (DISP2: OR=1.30, p=6.2´10-3; HLA-L: OR=0.75, 
p=1.6´10-6).  
A total of 70 lung function instruments were mapped to genome-wide significant (p<5.0´10-8) protein 
quantitative trait loci (pQTL) affecting the plasma levels of 64 different proteins (Supplementary Data 8), 
based on data from the Human Plasma Proteome Atlas36. Many of these pQTL targets are involved in 
regulation of immune and inflammatory responses, such as interleukins (IL21, IL1R1, IL17RD, IL18R1), 
MHC class I polypeptide-related sequences, transmembrane glycoproteins expressed by natural killer 
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cells, and members of the tumor necrosis receptor superfamily (TNFSF12, TNFRSF6B, TR19L). Other 
notable associations include NAD(P)H dehydrogenase [quinone] 1 (NQO1) a detoxification enzyme 
involved in protecting lung tissues in response to reactive oxidative stress (ROS) and promoting p53 
stability37. NQO1 is a target of the NFE2-related factor 2 (NRF2), a master regulator of cellular antioxidant 
response that has generated considerable interest as a chemoprevention target38, 39. 
Next, we analyzed genes where the lung function instruments were localized using curated pathways 
from the Reactome database. Significant enrichment (FDR q<0.05) was observed only for FEV1/FVC 
instruments in never smokers, with an over-representation of pathways involved in adaptive immunity and 
cytokine signaling (Supplementary Figure 6). Top-ranking pathways with q=2.2´10-6 included 
translocation of ZAP-70 to immunological synapse, phosphorylation of CD3 and TCR zeta chains, and 
PD-1 signaling. These findings are in line with the predominance of immune-related pQTL associations. 
Examining all instruments for FEV1 and FEV1/FVC identified significant over-representation (FDR q<0.05) 
of six immunologic signatures from the ImmuneSigDB collection40, including pathways implicated in host 
response to infection and immunization (Supplementary Figure 7). 
DISCUSSION 
Despite a substantial body of observational literature demonstrating an increased risk of lung cancer in 
individuals with pulmonary dysfunction2, 3, 4, 5, 6, 7, 41, confounding by shared environmental risk factors and 
high co-occurrence of lung cancer and airflow obstruction created uncertainty regarding the causal nature 
of this relationship. We comprehensively investigated this by characterizing shared genetic profiles 
between lung cancer and lung function, and interrogated causal hypotheses using Mendelian 
randomization, which overcomes many limitations of observational studies. We also provide insight into 
biological pathways underlying the observed associations by incorporating functional annotations into 
heritability analyses, assessing eQTL and pQTL effects of lung function instruments, and conducting 
pathway enrichment analyses. 
The large sample size of the UK Biobank allowed us to successfully create instruments for three 
pulmonary function phenotypes, FEV1, FEV1/FVC, and FVC. Although these phenotypes are closely 
related, they capture different aspects of pulmonary impairment, with FEV1 and FEV1/FVC used for 
diagnostic purposes in clinical setting. Our genetic instruments captured known and novel mechanisms 
involved in pulmonary function. Of the 73 novel variants identified here, many were in loci implicated in 
immune-related functions and pathologies. Examples include HORMAD2, which has been previously 
linked to inflammatory bowel disease42, 43 and tonsillitis44, and RIPOR1 (also known as FAM65A), which is 
part of a gene expression signature for atopy45. PIEZO1 is primarily involved in mechano-transduction 
and tissue differentiation during embryonic development46, 47, 48, however recent evidence has emerged 
delineating its role in optimal T-cell receptor activation and immune regulation49. BACH2, the new signal 
for FEV1/FVC in never smokers, is involved in alveolar macrophage function50, as well as selection-
mediated TP53 regulation and checkpoint control51. The lead variant identified here is independent 
(r2<0.05) of BACH2 loci nominally associated with lung function decline in a candidate gene study of 
COPD patients52, suggesting there may be differences in the genetic architecture of pulmonary traits in 
never smokers. 
Our genetic correlation analyses indicate shared genetic determinants between pulmonary function with 
anthropometric traits and cigarette smoking. Our results are in contrast with the recent findings of Wyss et 
al.24, who did not observe statistically significant genetic correlations for any pulmonary function 
phenotypes with height and smoking, as well FVC and FEV1/FVC, using publicly available summary 
statistics from the UKB and other studies of European ancestry individuals. In this respect, assessing 
genetic correlation within a single well-characterized population provides improved power while 
minimizing potential for bias and heterogeneity when combining data from multiple sources.  
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We observed statistically significant genetic correlations between pulmonary function impairment and 
lung cancer susceptibility for all lung cancer subtypes, except for never smokers. Reduced FEV1/FVC 
was significantly correlated with increased risk of lung cancer overall, squamous cell carcinoma, and 
adenocarcinoma. Significant genetic correlations with FEV1 and FVC were observed for lung cancer 
overall, in smokers, and for tumors with squamous cell histology, but not adenocarcinoma. Jiang et al.25 
reported a similar magnitude of genetic correlation with FEV1/FVC, but did not observe an association 
with FVC, and did not assess FEV1. Differences in our results may be attributable to their use of GWAS 
summary statistics for pulmonary phenotypes from the interim UK Biobank release. Our findings 
demonstrate substantial overlap in the genetic architecture of obstructive and neoplastic lung disease, 
particularly for highly conserved variants that are likely to be subject to natural selection, and super 
enhancers. However, genetic correlations do not support a causal interpretation, especially considering 
the shared heritability with potentially confounding traits, such as smoking and obesity.  
On the other hand, Mendelian randomization analyses revealed histology-specific effects of reduced 
FEV1 and FEV1/FVC on lung cancer susceptibility, suggesting that these indicators of impaired pulmonary 
function may be causal risk factors. Genetic predisposition to FEV1 impairment conferred an increased 
risk of lung cancer overall, particularly for squamous carcinoma. This relationship persisted after filtering 
potentially pleiotropic instruments and performing other sensitivity analyses, including multivariable 
Mendelian randomization and manual filtering of variants associated with smoking or adiposity. FEV1/FVC 
reduction appeared to increase the risk of lung adenocarcinoma, as well as lung cancer among never-
smokers. The latter finding is particularly compelling since it precludes confounding by smoking-related 
factors and demonstrates an association with the most clinically relevant pulmonary phenotype. The 
increased lung cancer risk in never smokers was also observed using genetic instruments developed 
specifically in never smokers and in sensitivity analyses using instruments from the population that also 
includes smokers. We hypothesize that the effects of pulmonary obstruction are mediated by chronic 
inflammation and immune response, which is supported by the overrepresentation of adaptive immunity 
and cytokine signaling pathways and pQTL effects among FEV1 and FEV1/FVC instruments.  
Examining lung eQTL effects of our genetic instruments identified additional relevant mechanisms, 
including gene expression of SECISBP2L and DISP2. SECISBP2L at 15q21 is essential for ciliary 
function53 and has an inhibitory effect on lung tumor growth by suppressing cell proliferation and 
inactivation of Aurora kinase A54. This gene was among several susceptibility regions identified in the 
most recent lung cancer GWAS16, and now we more conclusively establish impaired pulmonary function 
as the mechanism mediating SECISBP2L effects on risk of lung cancer overall, particularly 
adenocarcinoma. Less is known about DISP2, although it has been implicated in the conserved 
Hedgehog signaling pathway essential for embryonic development and cell differentiation55.  
One of the main challenges and outstanding questions in previous epidemiologic studies has been 
clarifying how smoking fits into the causal pathway between impaired pulmonary function and lung cancer 
risk. Are indicators of airway obstruction simply proxies for smoking-induced carcinogenesis? The 
association between reduced FEV1/FVC and risk of adenocarcinoma and lung cancer in never smokers 
observed in our Mendelian randomization analysis and in previous studies8, 9, argues against this 
simplistic explanation and points to alternative pathways. Chronic airway inflammation fosters a lung 
microenvironment with altered signaling pathways, aberrant expression of cytokines, chemokines, growth 
factors, and DNA damage-promoting agents, all of which promote cancer initaiton15. This mechanism may 
be particularly relevant for adenocarcinoma, which is the most common lung cancer histology in never 
smokers, arising from the peripheral alveolar epithelium that has less direct contact with inhaled 
carcinogens. 
Dysregulated immune function is a hallmark of lung cancer and COPD, with both diseases sharing similar 
inflammatory cell profiles characterized by macrophages, neutrophils, and CD4+ and CD8+ lymphocytes. 
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Immune cells in COPD and emphysema exhibit T helper 1 (Th1)/Th17 polarization, decreased 
programmed death ligand-1 (PD-L1) expression in alveolar macrophages, and increased production of  
interferon (IFN)-γ by CD8+ T cells56, a phenotype believed to prevail at tumor initiation, whereas 
established tumors are dominated by Th2/M2-like macrophages57. These putative mechanisms were 
highlighted in our pathway analysis, with an enrichment of genes involved in INF-γ, PD-1 and IL-1 
signaling among FEV1/FVC genetic instruments, and over-representation of pQTL targets in these 
pathways. Furthermore, a study of trans-thoracically implanted tumors in an emphysema mouse model 
demonstrates how this pulmonary phenotype results in impaired antitumor T cell responses at a critical 
point when nascent cancer cells evade detection and elimination by the immune system resulting in 
enhanced tumor growth58. 
Other relevant pathways implicating pulmonary dysfunction in lung cancer development include lung 
tissue destruction via matrix degrading enzymes and increased genotoxic and apoptotic stress resulting 
from cigarette smoke in conjunction with macrophage- and neutrophil-derived ROS15, 59. This may explain 
our findings for FEV1 and squamous carcinoma, for which cigarette smoking is a particularly dominant risk 
factor. Genetic predisposition to impaired FEV1 may create a milieu that promotes malignant 
transformation and susceptibility to external carcinogens and tissue damage, rather than increasing the 
likelihood of cigarette smoking. In our analysis we attempted to isolate the former pathway from the latter 
by carefully instrumenting pulmonary phenotypes and confirming that they are not associated with 
behavioral aspects of nicotine dependence. However, residual confounding by smoking cannot be entirely 
precluded, given its high genetic and phenotypic correlation with FEV1.  
The causal interpretation of our results critically depends on the validity of fundamental Mendelian 
randomization assumptions. We employed a range of estimation techniques with different underlying 
assumptions, as well as diagnostic tests, to interrogate the robustness of our results with respect to 
confounding, horizontal pleiotropy, and weak instrument bias. However, despite these efforts, residual 
confounding by related phenotypes, such as smoking, or subtle effects of population structure cannot be 
ruled out. In evaluating the contribution of our findings, several limitations should be acknowledged. Our 
approach to outlier removal based on Cochran’s Q statistic with modified second order weights may have 
been overly stringent; however, manually pruning based on such a large set of genetic instruments may 
not be feasible and may introduce additional bias, thus we feel this systematic conservative approach is 
justified. Furthermore, outlier removal did not have an adverse impact on instrument strength and 
precision of the MR analysis.  
In addition to pleiotropy, selection bias may also undermine the validity of a Mendelian Randomization 
study, particularly in the form of collider bias, if selection is a function of the exposure or outcome. In the 
context of the UKB, low participation (5.5%) may have resulted in an unrepresentative study population60, 
61. Although enrolment in the cohort was not explicitly contingent on cancer status or pulmonary function, 
it is likely that individuals who did not complete a spirometry assessment were more likely to be smokers 
and have poor lung function. Simulations by Gkatzionis & Burgess61 demonstrate that when the effect of a 
risk factor on selection is mild to moderate (odds of selection: 0.82 to 0.61), the type I error rate remains 
reasonable at 5.0-6.6%. The direction of the resulting bias depends on the direction and strength of the 
exposure (lung function) – confounder (smoking) relationship. In the context of our study, the causal 
effect may be underestimated since the confounder and exposure are both likely to increase non-
participation or result in missing spirometry data.  
Another limitation is that we did not assess the relationship between the velocity of lung function decline 
and lung cancer risk, which may also prove to be a risk factor and capture a different dimension of 
pulmonary dysfunction. Furthermore, since our study includes the largest GWAS of lung cancer cases in 
never smokers, this precludes a well-powered replication study in an independent European ancestry 
population. In addition, dichotomous stratification by smoking status does not permit an evaluation of the 
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relationship between pulmonary impairment and lung cancer risk across more granular levels of smoking. 
Lastly, in our efforts to present the most comprehensive assessment of pulmonary function impairment 
and lung cancer risk, a number of analyses were conducted, and it may be possible that some 
inconsistently observed associations were due to chance. 
Despite these limitations, important strengths of this work include the large sample size for instrument 
development and causal hypothesis testing. Our Mendelian randomization approach leveraged a large 
number of genetic instruments, including variants specifically associated with lung function in never 
smokers, while balancing the concerns related to genetic confounding and pleiotropy. By triangulating 
evidence from gene expression and plasma protein levels, we also provide a more enriched interpretation 
of the genetic effects of pulmonary function loci on lung cancer risk, which implicate immune-mediated 
pathways. Despite the small individual SNP effect sizes, combining multiple instruments revealed 
meaningful increases in lung cancer risk. A genetically predicted 10% reduction in FEV1/FVC confers an 
approximately 55% increased risk of lung cancer in never smokers, and a similar magnitude of effect was 
observed for FEV1 and squamous carcinoma. However, effects of FEV1/FVC on adenocarcinoma were 
more modest (16-23% increase). Taken together, these findings provide more robust etiological insight 
than previous studies that relied on using observed lung function phenotypes directly as putatively casual 
factors.  
As our understanding of the shared genetic and molecular pathways between lung cancer and pulmonary 
disease continues to evolve, identification of new susceptibility loci for pulmonary function and lung 
cancer risk may have important implications for future precision prevention and screening endeavors. 
Multiple genetic determinants of lung function are in pathways that contain druggable targets, based on 
our pQTL findings and previous reports18, which may open new avenues for chemoprevention or targeted 
therapies for lung cancers with an obstructive pulmonary etiology. In addition, with accumulating evidence 
supporting the effectiveness of low-dose computed tomography for lung cancer62, 63, impairment in FEV1 
and FEV1/FVC and their genetic determinants may provide additional information for refining risk-
stratification and screening eligibility criteria.  
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METHODS 
Study Populations 
The UK Biobank (UKB) is a population-based prospective cohort of over 500,000 individuals aged 40-69 
years at enrollment in 2006-2010 who completed extensive questionnaires on health-related factors, 
physical assessments, and provided blood samples64. Participants were genotyped on the UK Biobank 
Affymetrix Axiom array (89%) or the UK BiLEVE array (11%)64. Genotype imputation was performed using 
the Haplotype Reference Consortium data as the main reference panel as well as using the merged 
UK10K and 1000 Genomes (1000G) phase 3 reference panels64. Our analyses were restricted to 
individuals of predominantly European ancestry based on self-report and after excluding samples with 
either of the first two genetic ancestry principal components (PCs) outside of 5 standard deviations (SD) 
of the population mean. Samples with discordant self-reported and genetic sex were removed. Using a 
subset of genotyped autosomal variants with minor allele frequency (MAF)³0.01 and call rate ³97%, we 
filtered samples with call rates <97% or heterozygosity >5 standard deviations (SD) from the mean. First-
degree relatives were identified using KING65 and one sample from each pair was excluded, leaving at 
total of 413,810 individuals available for analysis. 
We further excluded 36,461 individuals without spirometry data, 207 individuals who only completed one 
blow (n=207), for whom reproducibility could not be assessed (Supplementary Figure 1). For the 
remaining subjects, we examined the difference between the maximum value per individual (referred to 
as the best measure) and all other blows. Values differing by more than 0.15L were considered non-
reproducible, based on standard spirometry guidelines66, and were excluded. Our analyses thus included 
372,750 and 370,638 individuals for of FEV1 and FVC, respectively. The best per individual measure 
among the reproducible blows was used to derive FEV1/FVC, resulting in 368,817 individuals. FEV1 and 
FVC values were then converted to standardized Z-scores with a mean of 0 and standard deviation (SD) 
of 1.  
The OncoArray Lung Cancer study has been previously described16. Briefly, this dataset consists of 
genome-wide summary statistics based on 29,266 lung cancer cases (11,273 adenocarcinoma, 7426 
squamous carcinoma) and 56,450 controls of predominantly European ancestry (≥80%) assembled from 
studies part of the International Lung Cancer Consortium. Summary statistics from the lung cancer GWAS 
were adjusted for appropriate covariates, including genetic ancestry PCs, and showed no signs of 
genomic inflation for lung cancer overall (lGC=1.0035) or for any subtypes, including adenocarcinoma 
(lGC=1.0050), squamous carcinoma (lGC=1.0051), and lung cancer in never smokers (lGC=1.0060). 
Informed consent was obtained from study participants in the UK Biobank and studies contributing data to 
the OncoArray Lung Cancer collaboration. UK Biobank received ethics approval from the Research 
Ethics Committee (REC reference: 11/NW/0382). Approval for OncoArray studies was obtained from 
each of the participating institutional research ethics review boards. 
Genome-Wide Association Analysis 
Genome-wide association analyses of pulmonary function phenotypes in the UK Biobank cohort were 
conducted using PLINK 2.0 (October 2017 version). We excluded variants out of with Hardy-Weinberg 
equilibrium at p<1´10-5 in cancer-free individuals, call rate <95% (alternate allele dosage required to be 
within 0.1 of the nearest hard call to be non-missing), imputation quality INFO<0.30, and MAF<0.005. To 
minimize potential for reverse causation, prevalent lung cancer cases, defined as diagnoses occurring up 
to 5 years before cohort entry and incident cases occurring within 2 years of enrollment, were excluded 
(n=738). Linear regression models for pulmonary function phenotypes (standardized Z-scores for FEV1 
and FVC; untransformed FEV1/FVC ratio bounded by 0 and 1) were adjusted for age, age2, sex, 
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genotyping array and 15 PCs  to permit an assessment of heritability (hg) and genetic correlation (rg) with 
height, smoking (status and pack-years), and anthropometric traits.  
Heritability and Genetic Correlation 
LD Score regression17 was used to estimate hg for each lung phenotype and rg with lung cancer and other 
traits. To better capture LD patterns present in the UKB data, we generated LD scores for all variants that 
passed QC with MAF>0.0001 using a random sample of 10,000 UKB participants. UKB LD scores were 
used to estimate hg for each lung phenotype and rg with other non-cancer traits. Genetic correlation with 
lung cancer was estimated using publicly available LD scores based on the 1000G phase 3 reference 
population (n=1,095,408 variants). 
To assess the importance of specific functional annotations in SNP-heritability, we partitioned trait-
specific heritability using stratified-LDSC67. The analysis was performed using 86 annotations (baseline-
LD model v2.1), which incorporated MAF-adjustment and other LD-related annotations, such as predicted 
allele age and recombination rate20, 22. The MHC region was excluded from partitioned heritability 
analyses. Enrichment was considered statistically significant if p<8.5´10-4, which reflects Bonferroni 
correction for 59 annotations (functional categories with and without a 500 bp window around it were 
considered as the same annotation). 
Development of Genetic Instruments for Pulmonary Function 
For the purpose of instrument development, a two-stage genome-wide analysis was employed, with a 
randomly sampled 70% of the cohort used for discovery and the remaining 30% reserved for replication. 
In addition to age, age2, sex, genotyping array and 15 PC’s, models were adjusted for covariates that 
explain a substantial proportion of variation in pulmonary phenotypes, such as smoking and height, in 
order to decrease the residual variance and help isolate the relevant genetic signals. Specifically, we 
adjusted for height, height2, and cigarette pack-year categories (0, corresponding to never-smokers, >0-
10, >10-20, >20-30, >30-40, and >40). Other covariates, such as UKB assessment center (Field 54), use 
of an inhaler prior to spirometry (Field 3090), and blow acceptability (Field 3061) were considered. 
However, these covariates did not explain a substantial proportion of phenotype variation and had low 
variable importance metrics (lmg<0.01), and thus were not included in our final models. Instruments were 
selected from independent associated variants (LD r2<0.05 in a clumping window of 10,000 kb) with 
P<5´10-8 in the discovery stage and P<0.05 and consistent direction of effect in the replication stage. 
Since the primary goal of our GWAS was to develop a comprehensive set of genetic instruments we 
applied a less stringent replication threshold in anticipation of subsequent filtering based on potential 
violation of Mendelian randomization assumptions. 
Mendelian Randomization 
Mendelian randomization (MR) analyses were carried out to investigate the potential causal relationship 
between impaired pulmonary function and lung cancer risk. Genetic instruments excluded multi-allelic and 
non-inferable palindromic variants with intermediate allele frequencies (MAF>0.42). Odds ratios (OR) and 
corresponding 95% confidence intervals were obtained using the maximum likelihood and inverse 
variance weighted multiplicative random-effects (IVW-RE) estimators28, 29. Effects for FEV1 and FVC were 
estimated for a genetically predicted 1-SD decrease in the standardized Z-score. For FEV1/FVC, we 
modeled cancer risk corresponding to a 10% decrease in the ratio. Sensitivity analyses included the 
weighted median (WM) estimator30, which provides unbiased estimates when up to 50% of the weights 
are from invalid instruments, and MR RAPS (Robust Adjusted Profile Score), which incorporates random 
effect and robust loss functions to limit the influence of potentially pleiotropic instruments. MR RAPS 
assumes balanced (mean 0) horizontal pleiotropy. In contrast to IVW-RE, MR RAPS models idiosyncratic 
and systematic pleiotropy effects as additive, rather than multiplicative31. Using MR estimation techniques 
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with different underlying statistical models allows for a more comprehensive assessment of the 
robustness of our results with respect to violations of MR assumptions. We also applied the following 
diagnostic tests: i) significant (p<0.05) deviation of the MR Egger intercept (b0 Egger) from 0, as a test for 
directional pleiotropy68; ii) I2GX statistic <0.90 indicative of regression dilution bias and inflation in the MR 
Egger pleiotropy test due to violation of the no measurement error (NOME) assumption68; iii) Cochran’s 
Q-statistic with modified second order weights to asses heterogeneity (p-value<0.05) indicative of 
(balanced) horizontal pleiotropy69.  
All statistical analyses were conducted using R (version 3.6.1). Mendelian randomization analyses were 
conducted using the TwoSampleMR R package (version 0.4.23).  
Functional Characterization of Lung Function Instruments 
In order to characterize functional pathways that are represented by the genetic instruments for FEV1 and 
FEV1/FVC, we examined effects on gene expression in lung tissues from 409 subjects from the Laval 
eQTL study35. Lung function instruments with significant (Bonferroni p-value<0.05) eQTL effects were 
used as instruments to estimate the effect of the gene expression on lung cancer risk. For genes with 
multiple eQTLs, independent variants (LD r2<0.05) were used to obtain IVW estimates of the predicted 
effects of increased gene expression on lung cancer risk. For genes with a single eQTL, OR estimates 
were obtained using the Wald method. Next, we examined data from the genetic atlas of the human 
plasma proteome36, queried using PhenoScanner70, to assess whether any of the genetic instruments for 
FEV1 and FEV1/FVC had significant (p<5´10-8) effects on intracellular protein levels. Lastly, we 
summarized the pathways represented by the genes where the lung function instruments were localized 
using pathway enrichment analysis via the Reactome database and ImmuneSigDB (collection C7 from 
MSigDB). 
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FIGURE TITLES AND LEGENDS 
Figure 1: Functional partitioning of array-based heritability for each pulmonary function phenotype.  
a. The magnitude of category-specific enrichment and corresponding -log10(p-value) for 22 distinct 
functional annotations that were significantly enriched for all three phenotypes (FEV1, FVC, FEV1/FVC). 
b. The proportion of heritability, Pr(hg), accounted for by each functional annotation with corresponding 
standard errors. Functional annotation categories are not mutually exclusive.  
Figure 2: Genetic correlation (rg) between pulmonary function phenotypes and anthropometric and 
smoking phenotypes.  
Estimates for rg are based on UK Biobank-specific LD scores. The colors in the Circos plot correspond to 
the direction of genetic correlation, with warm shades denoting positive relationships and cool tones 
depicting negative correlations. The width of each band in the Circos plot is proportional to the magnitude 
of the absolute value of the rg estimate. 
Figure 3: Genetic correlation (rg) between pulmonary function phenotypes and lung cancer subtypes.  
Estimates of rg are based on genome-wide summary statistics from the UK Biobank cohort for pulmonary 
traits, and the International Lung Cancer Consortium OncoArray study for lung cancer. Genetic 
correlations have been re-scaled to depict associations between impaired (reduced) pulmonary function 
and lung cancer risk. The colors in the Circos plot correspond to the direction of genetic correlation, with 
warm shades depicting positive correlations between impaired pulmonary function and lung cancer risk, 
and gray tones corresponding to inverse and null correlations. The width of each band in the Circos plot is 
proportional to the magnitude of the absolute value of the rg estimate. 
Figure 4: Odds ratios (OR) and 95% confidence intervals for the effect of impaired pulmonary function on 
lung cancer risk, estimated using Mendelian randomization (MR).  
Multiple MR estimation methods were applied to the International Lung Cancer Consortium OncoArray 
dataset, comprised of 29,266 lung cancer cases (11,273 adenocarcinoma, 7,426 squamous cell 
carcinoma) and 56,450 controls to assess the causal relevance of impaired FEV1 (a), FVC (b), and 
FEV1/FVC (c). MR estimates based on the full set of genetic instruments are compared to estimates after 
excluding outliers suspected of violating MR assumptions. Only associations with p-values less than 0.25 
are labeled. Proportion of variation explained by the genetic instruments was estimated in a separate 
replication sample of over 110,000 individuals from the UK Biobank.  
Figure 5: Scatterplot depicting the Mendelian randomization (MR) results for FEV1/FVC in never smokers 
and lung cancer in never smokers (2355 cases, 7504 controls).  
The scatterplot illustrates the effects of individual instruments on FEV1/FVC and lung cancer risk, 
highlighting potentially invalid outlier instruments that were filtered. Individual instrument effects in the 
scatterplot correspond to a 1-unit decrease in FEV1/FVC, but the summary odds ratios (ORs) for lung 
cancer have been rescaled to correspond to a 10% decrease in FEV1/FVC. Summary log(ORs) based on 
different MR estimators correspond to the slope of the lines in scatterplot.  
